160 related articles for article (PubMed ID: 33473167)
1. Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer.
Lu H; Cunnea P; Nixon K; Rinne N; Aboagye EO; Fotopoulou C
Br J Cancer; 2021 Mar; 124(7):1286-1293. PubMed ID: 33473167
[TBL] [Abstract][Full Text] [Related]
2. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
[TBL] [Abstract][Full Text] [Related]
3. KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer.
De Donato M; Babini G; Mozzetti S; Buttarelli M; Ciucci A; Arduini G; De Rosa MC; Scambia G; Gallo D
J Exp Clin Cancer Res; 2020 Nov; 39(1):265. PubMed ID: 33250051
[TBL] [Abstract][Full Text] [Related]
4. Fully sialylated alpha-chain of complement 4-binding protein (A2160): a novel prognostic marker for epithelial ovarian carcinoma.
Matsuo K; Tanabe K; Ikeda M; Shibata T; Kajiwara H; Miyazawa M; Miyazawa M; Hayashi M; Shida M; Hirasawa T; Roman LD; Mikami M
Arch Gynecol Obstet; 2018 Mar; 297(3):749-756. PubMed ID: 29340789
[TBL] [Abstract][Full Text] [Related]
5. Prostaglandin D2 expression is prognostic in high‑grade serous ovarian cancer.
Alves MR; Do Amaral NS; Marchi FA; Silva FIB; Da Costa AABA; Carvalho KC; Baiocchi G; Soares FA; De Brot L; Rocha RM
Oncol Rep; 2019 Apr; 41(4):2254-2264. PubMed ID: 30720106
[TBL] [Abstract][Full Text] [Related]
6. High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer.
Li M; Cheng X; Rong R; Gao Y; Tang X; Chen Y
BMC Cancer; 2020 Oct; 20(1):1032. PubMed ID: 33109151
[TBL] [Abstract][Full Text] [Related]
7. Prognostic role of pathologic response and cytoreductive status at interval debulking surgery after neoadjuvant chemotherapy for advanced epithelial ovarian cancer.
Liang MI; Prendergast EN; Staples JN; Holschneider CH; Cohen JG; Cass I
J Surg Oncol; 2019 Sep; 120(4):779-785. PubMed ID: 31283034
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
[TBL] [Abstract][Full Text] [Related]
9. Prediction of Optimal Cytoreductive Surgery of Serous Ovarian Cancer With Gene Expression Data.
Abdallah R; Chon HS; Bou Zgheib N; Marchion DC; Wenham RM; Lancaster JM; Gonzalez-Bosquet J
Int J Gynecol Cancer; 2015 Jul; 25(6):1000-9. PubMed ID: 26098088
[TBL] [Abstract][Full Text] [Related]
10. CD24-targeted intraoperative fluorescence image-guided surgery leads to improved cytoreduction of ovarian cancer in a preclinical orthotopic surgical model.
Kleinmanns K; Fosse V; Davidson B; de Jalón EG; Tenstad O; Bjørge L; McCormack E
EBioMedicine; 2020 Jun; 56():102783. PubMed ID: 32454402
[TBL] [Abstract][Full Text] [Related]
11. BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study.
Marchetti C; De Leo R; Musella A; D'Indinosante M; Capoluongo E; Minucci A; Benedetti Panici P; Scambia G; Fagotti A
Ann Surg Oncol; 2018 Nov; 25(12):3701-3708. PubMed ID: 30128899
[TBL] [Abstract][Full Text] [Related]
12. Cardiophrenic lymph node resection in cytoreduction for primary advanced or recurrent epithelial ovarian carcinoma: a cohort study.
Lopes A; Rangel Costa RL; di Paula R; Anton C; Calheiros Y; Sartorelli V; Kanashiro YM; de Lima JA; Yamada A; Pinto GLS; Vianna MR; Nogueira Dias Genta ML; Ribeiro U; Dos Santos MO
Int J Gynecol Cancer; 2019 Jan; 29(1):188-194. PubMed ID: 30640703
[TBL] [Abstract][Full Text] [Related]
13. Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan.
Kang JH; Lai YL; Cheng WF; Kim HS; Kuo KT; Chen YL; Lee YY
Sci Rep; 2020 Nov; 10(1):20012. PubMed ID: 33203969
[TBL] [Abstract][Full Text] [Related]
14. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
Xu L; Wu Y; Che X; Zhao J; Wang F; Wang P; Qu X; Liu Y; Li Z
DNA Cell Biol; 2019 Dec; 38(12):1519-1528. PubMed ID: 31657627
[TBL] [Abstract][Full Text] [Related]
15. Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer.
Hillman RT; Chisholm GB; Lu KH; Futreal PA
J Natl Cancer Inst; 2018 Mar; 110(3):265-72. PubMed ID: 29584920
[TBL] [Abstract][Full Text] [Related]
16. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma.
Matsuo K; Sheridan TB; Mabuchi S; Yoshino K; Hasegawa K; Studeman KD; Im DD; Rosenshein NB; Roman LD; Sood AK
Gynecol Oncol; 2014 Jun; 133(3):473-9. PubMed ID: 24674832
[TBL] [Abstract][Full Text] [Related]
18. Proteases and their inhibitors as prognostic factors for high-grade serous ovarian cancer.
Trudel D; Avarvarei LM; Orain M; Turcotte S; Plante M; Grégoire J; Kappelhoff R; Labbé DP; Bachvarov D; Têtu B; Overall CM; Bairati I
Pathol Res Pract; 2019 Jun; 215(6):152369. PubMed ID: 30987833
[TBL] [Abstract][Full Text] [Related]
19. Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma.
Matsuo K; Wong KK; Fotopoulou C; Blake EA; Robertson SE; Pejovic T; Frimer M; Pardeshi V; Hu W; Choi JS; Sun CC; Richmond AM; Marcus JZ; Hilliard MAM; Mostofizadeh S; Mhawech-Fauceglia P; Abdulfatah E; Post MD; Saglam O; Shahzad MMK; Karabakhtsian RG; Ali-Fehmi R; Gabra H; Roman LD; Sood AK; Gershenson DM
J Surg Oncol; 2018 Feb; 117(2):236-244. PubMed ID: 28787528
[TBL] [Abstract][Full Text] [Related]
20. Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer.
Tucker SL; Gharpure K; Herbrich SM; Unruh AK; Nick AM; Crane EK; Coleman RL; Guenthoer J; Dalton HJ; Wu SY; Rupaimoole R; Lopez-Berestein G; Ozpolat B; Ivan C; Hu W; Baggerly KA; Sood AK
Clin Cancer Res; 2014 Jun; 20(12):3280-8. PubMed ID: 24756370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
